Compare Amphastar Pharmaceuticals Inc (AMPH) vs Coupang Inc (CPNG) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Coupang (CPNG) trades at $18.80, down 1.88% on the day, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $34.53B in 2025, though net income margins remain thin at 0.6%. The stock faces headwinds from a recent $409 million regulatory fine in South Korea over a data breach, as reported by Reuters on June 10, 2026, but maintains strong analyst support with 14 buy ratings.

The outlook is cautiously optimistic given Wall Street's $25.80 price target, implying 37% upside, but risks include regulatory scrutiny and volatile earnings. Positive cash flow from operations of $1.77B in 2025 supports growth initiatives, yet investors must weigh competitive pressures in e-commerce against the company's scale advantages.